Medpace Holdings, Inc. $MEDP Shares Bought by NorthCrest Asset Manangement LLC

NorthCrest Asset Manangement LLC grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 73.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,470 shares of the company’s stock after purchasing an additional 1,474 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in Medpace were worth $2,036,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quent Capital LLC acquired a new position in Medpace during the 3rd quarter valued at approximately $25,000. Optiver Holding B.V. bought a new position in Medpace during the 3rd quarter worth $27,000. Quarry LP acquired a new stake in Medpace in the third quarter worth $35,000. Root Financial Partners LLC acquired a new stake in Medpace in the third quarter worth $38,000. Finally, Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

NASDAQ:MEDP opened at $456.93 on Tuesday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The stock has a market cap of $12.97 billion, a price-to-earnings ratio of 29.86, a PEG ratio of 2.17 and a beta of 1.44. The business has a fifty day moving average of $506.24 and a 200-day moving average of $538.51.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company’s revenue was up 32.0% on a year-over-year basis. During the same period in the previous year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a report on Friday, February 13th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and cut their price objective for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Royal Bank Of Canada began coverage on shares of Medpace in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 target price for the company. Mizuho set a $582.00 target price on shares of Medpace in a research report on Wednesday, February 11th. Finally, Truist Financial dropped their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $486.67.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.